Clinical trial
Wearable Device-Based Long-Term Management of Coronary Artery Disease: The OPPO-WATCH Study
NCT07912671 is registered in ClinicalTrials.gov with China National Center for Cardiovascular Diseases as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Wearable Device-Based Long-Term Management of Coronary Artery Disease: The OPPO-WATCH Study
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- December 31, 2028
- Enrollment
- 400 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chronic coronary syndrome
Arms
As registered; 2 arms.
-
Wearable Device-Based Management Group
Participants receive wearable device-based, LE8-guided management with access to their monitoring data, health and medication reminders, and individualized LE8 score feedback, together with routine in-person cardiology outpatient follow-up every three months for 12 months.
-
Data-Blinded Wearable Monitoring Group
Participants wear a smartwatch for data collection but do not have access to monitoring data, health or medication reminders, or Life's Essential 8 (LE8) score feedback. They receive routine in-person cardiology outpatient follow-up every three months for 12 months.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Change in Life's Essential 8 (LE8) Cardiovascular Health Score
The primary outcome is the between-group difference in the change in the American Heart Association's Life's Essential 8 (LE8) cardiovascular health score from baseline to 12 months. The LE8 score is calculated automatically by the cloud-based system using data on eight cardiovascular health components: physical activity, sleep health, nicotine exposure, diet, blood pressure, blood glucose, blood lipids, and body mass index. Each component is scored from 0 to 100, and the overall LE8 score is calculated as the unweighted average of the eight component scores, ranging from 0 to 100. Higher scores indicate better cardiovascular health.
Lead sponsor's other trials
China National Center for Cardiovascular Diseases, most recent start first.
+264 more trials See the organization page
Similar trials
Same condition (Coronary Disease) and phase, most recent start first.
+411 more trials See the condition page